Radiology and Oncology (Nov 2021)

Clinical outcomes in stage III non-small cell lung cancer patients treated with durvalumab after sequential or concurrent platinum-based chemoradiotherapy – single institute experience

  • Vrankar Martina,
  • Stanic Karmen,
  • Jelercic Stasa,
  • Ciric Eva,
  • Vodusek Ana Lina,
  • But-Hadzic Jasna

DOI
https://doi.org/10.2478/raon-2021-0044
Journal volume & issue
Vol. 55, no. 4
pp. 482 – 490

Abstract

Read online

Chemoradiotherapy (ChT-RT) followed by 12-month durvalumab is the new standard treatment for unresectable stage III non-small cell lung cancer. Survival data for patients from everyday routine clinical practice is scarce, as well as potential impact on treatment efficacy of sequential or concomitant chemotherapy and the usage of gemcitabine.

Keywords